Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The clinical effectiveness of dabrafenib plus trametinib is based on a single-arm trial (BRF113928) with a small sample size, which raises concerns about the robustness of the evidence. Although the trial showed a 64% overall response rate and median overall survival of 17 months, the lack of direct comparison with standard treatments like pembrolizumab plus platinum chemotherapy introduces significant uncertainty regarding its relative efficacy. The committee noted that the evidence from various sources was uncertain, leading to a B++ rating.
Cost effectiveness
The cost-effectiveness estimates for dabrafenib plus trametinib are considered acceptable within the Healthcare framework, with the committee concluding that the most plausible ICER falls within the range typically deemed cost-effective. However, the uncertainty surrounding the estimates due to the small trial population and lack of direct comparisons necessitated a cautious approach, resulting in a rating of A.
Quality of life
The committee acknowledged that dabrafenib plus trametinib could improve quality of life for patients with BRAF V600 mutation-positive advanced NSCLC, particularly as an oral therapy that reduces the need for hospital visits. However, the evidence for HRQoL improvements was not extensively detailed in the document, leading to a moderate rating of A.
Supporting Domains
Safety and Adverse Effects
The safety profile of dabrafenib plus trametinib was described as manageable, with mostly mild to moderate adverse events. The committee noted that serious adverse events were rare, supporting a very good tolerability rating of A+. However, the absence of extensive comparative safety data with standard treatments limits the rating.
Comparator Selection
The primary comparator selected was pembrolizumab plus platinum chemotherapy, which is appropriate for the first-line treatment of advanced NSCLC. However, the lack of direct comparative evidence between dabrafenib plus trametinib and this comparator, along with the reliance on indirect comparisons, led to a B++ rating.
Patient Population and Subgroups
The trial population included patients with BRAF V600E mutation-positive advanced NSCLC, which is the target population for this appraisal. While the population is relevant, the small sample size and limited subgroup analysis slightly reduce generalizability, resulting in a rating of A.
Care Pathway Integration
Dabrafenib plus trametinib can be integrated into existing care pathways with minor adjustments, primarily due to its oral administration, which reduces the need for hospital visits. This ease of integration supports a rating of A+.
Resource Use and Cost Implications
The committee concluded that the budget impact of dabrafenib plus trametinib is manageable and aligns with Healthcare planning. The potential for cost savings due to reduced hospital visits supports a rating of A.
Evidence Quality and Robustness
The evidence base is primarily derived from a single-arm trial with a small sample size, which raises concerns about robustness and potential biases. While the trial design was acceptable, the lack of multiple rigorous studies leads to a B++ rating.
Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty surrounding the clinical effectiveness and cost-effectiveness estimates due to the small trial population and indirect comparisons. This uncertainty, coupled with the potential for unmet needs in the target population, results in a rating of B+.
